Skip to main content
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.
- Author(s): Geiger, Jessica L;
- Bauman, Julie E;
- Gibson, Michael K;
- Gooding, William E;
- Varadarajan, Prakash;
- Kotsakis, Athanasios;
- Martin, Daniel;
- Gutkind, Jorge Silvio;
- Hedberg, Matthew L;
- Grandis, Jennifer R;
- Argiris, Athanassios
- et al.
Published Web Locationhttps://doi.org/10.1002/hed.24501
BackgroundPatients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) demonstrate aberrant activation of the phosphotidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway. We examined the efficacy of everolimus, an mTOR inhibitor, in patients with recurrent or metastatic HNSCC.
MethodsThis single-arm phase II study enrolled biomarker-unselected patients with recurrent or metastatic HNSCC who failed at least 1 prior therapy. Everolimus was administered until progressive disease or unacceptable toxicity. Primary endpoint was clinical benefit rate (CBR). Secondary endpoints included progression-free survival (PFS), overall survival (OS), and evaluation of tissue and serum biomarkers related to the PIK3CA pathway.
ResultsSeven of 9 patients treated in the first stage were evaluable. No objective responses were seen; CBR was 28%. Three patients discontinued everolimus because of toxicity. Median PFS and OS were 1.5 and 4.5 months, respectively. No activating PI3K mutations were identified in available tumor tissue.
ConclusionEverolimus was not active as monotherapy in unselected patients with recurrent/metastatic HNSCC. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1759-1764, 2016.
For improved accessibility of PDF content, download the file to your device.